MGTX vs. CRBU, BDTX, TNYA, JSPR, CADL, SOPH, AVXL, TRML, IVVD, and AURA
Should you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), Tenaya Therapeutics (TNYA), Jasper Therapeutics (JSPR), Candel Therapeutics (CADL), SOPHiA GENETICS (SOPH), Anavex Life Sciences (AVXL), Tourmaline Bio (TRML), Invivyd (IVVD), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
Caribou Biosciences (NASDAQ:CRBU) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
In the previous week, Caribou Biosciences had 14 more articles in the media than MeiraGTx. MarketBeat recorded 15 mentions for Caribou Biosciences and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.15 beat Caribou Biosciences' score of -0.22 indicating that Caribou Biosciences is being referred to more favorably in the media.
MeiraGTx has lower revenue, but higher earnings than Caribou Biosciences. MeiraGTx is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Caribou Biosciences has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 9.7% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
MeiraGTx received 170 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 71.10% of users gave MeiraGTx an outperform vote while only 53.13% of users gave Caribou Biosciences an outperform vote.
Caribou Biosciences has a net margin of -345.05% compared to Caribou Biosciences' net margin of -651.19%. MeiraGTx's return on equity of -33.42% beat Caribou Biosciences' return on equity.
Caribou Biosciences currently has a consensus target price of $21.50, suggesting a potential upside of 534.22%. MeiraGTx has a consensus target price of $26.00, suggesting a potential upside of 355.34%. Given MeiraGTx's higher possible upside, equities research analysts plainly believe Caribou Biosciences is more favorable than MeiraGTx.
Summary
Caribou Biosciences beats MeiraGTx on 11 of the 18 factors compared between the two stocks.
Get MeiraGTx News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MeiraGTx Competitors List
Related Companies and Tools
